Health services

Tender description

NHS England is intending to commission provider(s) to carry out percutaneous mitral valve leaflet repair services for primary mitral regurgitation across the following four regions: East of England, Midlands, North East and Yorkshire and South East. It is therefore the Commissioner's intention to split any future selection process into four lots, subject to responses to this PIN and market engagement questionnaire. (Please see details further down on how to access the questionnaire.) NHS Arden and Greater East Midlands Commissioning Support Unit (AGCSU), on behalf of NHS England — Specialised Commissioning is carrying out a market engagement exercise for the provision of Percutaneous Mitral Valve Leaflet Repair Services for Primary Mitral Regurgitation across four regions. NHS England intends to commission the services by splitting the requirement into four lots. NHS England is proposing that these lots will be split as follows: Lot 1: East of England, Lot 2: Midlands, Lot 3: North East and Yorkshire, Lot 4: South East. The mitral valve’s normal function is essential in ensuring one way forward flow of blood from the left atrium into the left ventricle. Mitral regurgitation occurs when the mitral valve fails to close properly following ventricular filling: blood fails to flow through the aortic valve and into the aorta. This regurgitated blood leaks back through the mitral valve into the left atrium and can cause heart failure if a sufficiently large enough volume of blood regurgitates into the left ventricle. Percutaneous mitral valve leaflet repair (PMVLR) is currently commissioned for primary or degenerative mitral regurgitation. The procedure is not commissioned for individuals with secondary (functional) mitral regurgitation. Following publication of the commissioning policy, specialised Commissioning agreed that arrangements should be put in place to provide rapid access to the procedure. For this reason on an initial basis the three providers that had taken part in the earlier Commissioning through Evaluation scheme a Commissioning through Evaluation (CtE) process, three providers were commissioned selected to perform PMVLR: • London: Royal Brompton and Harefield NHS Foundation Trust, • NW: Manchester University NHS Foundation Trust, • SW: University Hospitals Bristol and Weston NHS Foundation Trust. Any future provider selection process is therefore to cover the additional four regions on an interim basis for a period of 2 years, with the option for the Commissioner to extend the contract(s) for a further 12 months (i.e. 2 + 1), subject to market feedback and internal approval. This service is expected to commence on 1 May 2021. The aim of the market engagement exercise is to inform providers on the potential opportunity and to assist the commissioners in deciding on the most appropriate strategy for the future provider selection approach. Organisations must respond to this PIN notice/questionnaire if they wish to be included in any future selection process. If you wish to express an interest and complete the market engagement questionnaire, please register on the EU supply website https://uk.eu-supply.com/login.asp?B=UK The reference for this questionnaire is Quote/tender 40570 — ‘Percutaneous Mitral Valve Leaflet Repair for Primary Mitral Regurgitation’. Providers must complete and submit their questionnaire response by 12.00 noon on Monday 17 August 2020. Any submitted response to this PIN notice will not automatically entitle your involvement in any future procurement process. Any procurement conducted as a result of this notice will be dependent on the level of interest identified in response to this PIN. Arden and GEM CSU welcomes and appreciates your organisation’s effort for registering interest to participate within the market engagement related to this PIN notice, but wishes to stress that your involvement at this stage will not carry any commercial advantage in any future procurement process.